Inovio Pharmaceuticals, Inc. (INO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 87/100 (CRITICAL), 3.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 25.41% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Upcoming Catalysts
Recent News & SEC Filings
- Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
- Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
- INOVIO to Participate in Upcoming Investor Conferences
- Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...
- Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
- INOVIO to Report Second Quarter Financial Results on August 12, 2026
- INOVIO to Participate in Upcoming Scientific and Investor Conferences
- INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Inovio Pharmaceuticals, Inc..
Full INO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.